Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. - Wikidata - awgldk - TriplyDB

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

http://www.wikidata.org/entity/Q37473376

about

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.Drug-related myopathies of which the clinician should be aware Co-medication of statins with contraindicated drugs.Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information.A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.Update on toxic myopathies.Pravastatin-induced rhabdomyolysis and purpura fulminans in a patient with chronic renal failure.Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin.Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs

P2860

Q26853571-F3529128-1CD6-4C22-8ABD-91F3A48D6138 Q34276618-55C84926-08EB-430A-9DC9-3ECA59605866 Q34903761-FDEAE7B6-688A-44DC-B9BD-5EF30A581339 Q34974845-894C93F6-570D-46A8-AC14-B8ED421259AD Q35561151-922DAE9B-3171-4317-96E3-C55E88B86391 Q35855012-0CAAA218-BBC3-4171-AE15-73A5ACE7CA3B Q35915932-D0FB6461-0E8B-463D-89B3-D2CA35A0F438 Q36203546-33EF6074-2743-4F08-A523-7622FC80D076 Q36809811-14B7AD42-7A8F-451E-BE57-FFE1BEF51C26 Q37316562-3B1C6122-CF15-4C8C-95EF-58058E3A04A5 Q37473382-88E2BD3A-ECEA-45BD-AAB4-224A37572365 Q37942033-7AE2940D-FD20-48C3-8A0B-90A271DB8A57 Q41871657-27E561F2-D259-47B3-B6CF-E17992FE3365 Q42393296-27F78AF3-5F3B-4766-9AB1-D5BCDC83A080 Q42688670-46F45BDB-7ACB-4C04-A4EB-696A5EDFE911 Q42704777-16E8B35C-D62D-43DC-9C5D-FD10AE998A26 Q45749050-F698422D-3902-4ED0-831E-74952D9B6BA1 Q46136908-488D11CE-D1DC-4C2D-A269-4C9D90CDBA02 Q48202863-4C4115FA-6EDB-477B-A0EB-F1B5A65FC766 Q59133164-66D85CA4-047E-4ACD-BB1D-32CE6500F6C0

P2860

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

http://www.wikidata.org/entity/Q37473376

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@en

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@nl

type

label

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@en

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@nl

prefLabel

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@en

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@nl

P1433

Q37473376-8C9B2A2D-5278-4B8C-A4EB-400E2C136426

P1476

Q37473376-5B25EA26-1A39-4760-8500-D75F03C744E0

P2093

Q37473376-09118A14-78AD-4BB5-8785-C7C8B1D74832

Q37473376-0A6978FC-0072-4794-8B61-B49E1E6D4F30

Q37473376-5C1B4122-177B-4EA1-8C3E-733104D48DBC

Q37473376-6401824F-0842-4FD3-B063-307A80F5FCF5

Q37473376-8D1C49B8-BB97-4A8F-8694-1AAE9330C34F

Q37473376-C21932EE-D77F-4049-97CE-8D775BD7B065

Q37473376-FC70A981-1E2E-470D-861D-159269554ABC

P2860

Q37473376-05C37F22-8E1E-45E9-ABC8-9AE44D7261BC

Q37473376-3DD8D676-DF3A-4C32-8EF1-6AAECB2A7003

Q37473376-45366FDA-7699-49D3-84C0-8AEED6B2C5A2

Q37473376-5674BF45-3D53-46C8-89E9-EBDC92AD32A3

Q37473376-61CC5947-8EF8-4836-B238-464D90B0D1C3

Q37473376-63749C22-CF70-45AE-90AA-B520F7E883C1

Q37473376-65AD6FC5-756B-43D0-8895-BFB2E5F5BC0D

Q37473376-68EDDA7C-503C-44F1-99D6-DD26F815F0DC

Q37473376-734131A7-3200-4422-AFD2-90637FD3F6D2

Q37473376-77BAA91E-F27D-4AED-BF32-F954441F18BA

P304

Q37473376-CF97A3A6-01BE-4EED-8A65-7A6EC730ECC5

P31

Q37473376-D93ECC2C-12E5-4DD3-B857-5E8EF6114F45

P356

Q37473376-0FE0555D-B95F-43FF-88A0-8781EDAF2D7E

P433

Q37473376-8AF133ED-FCBE-4D1A-8457-54FF65AED22C

P478

Q37473376-6FA45901-4294-4BE1-8902-71523BCED640

P577

Q37473376-F4792CF6-522A-43D4-9A36-62C3193465AD

P698

Q37473376-A84CD57A-A182-4DEA-83D2-0E2AEEFA7C40

P932

Q37473376-AEAE96EE-DC05-4B6C-A9C1-646BC56FE4D8

P356

P1433

Pharmacoepidemiology and Drug Safety

P1476

Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

@en

P2093

Allen D Brinker

http://www.w3.org/2001/XMLSchema#string

Andrew Mosholder

http://www.w3.org/2001/XMLSchema#string

Christopher Rowan

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Barrett

http://www.w3.org/2001/XMLSchema#string

Jennie Chang

http://www.w3.org/2001/XMLSchema#string

Mark Avigan

http://www.w3.org/2001/XMLSchema#string

Parivash Nourjah

http://www.w3.org/2001/XMLSchema#string

P2860

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

HMG-CoA reductase inhibitors and myotoxicity.

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

P304

301-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.1711

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19206087

http://www.w3.org/2001/XMLSchema#string

P932

3890413

http://www.w3.org/2001/XMLSchema#string